Impact of ITH on PRAD patients and feasibility analysis of the positive correlation gene MYLK2 applied to PRAD treatment

IntroductionProstate adenocarcinoma (PRAD) is an extremely widespread site of urological malignancy and is the second most common male cancer in the world. Currently, research progress in immunotherapy for prostate treatment is slower compared to other tumours, which is mainly considered to be cause...

Full description

Bibliographic Details

Published in:	Frontiers in Genetics
Main Authors:	Chuanyu Ma, Guandu Li, Xiaohan Song, Xiaochen Qi, Tao Jiang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-05-01
Subjects:	prostate adenocarcinoma (PRAD) intra-tumour heterogeneity (ITH) prognosis immunotherapy MYLK2
Online Access:	https://www.frontiersin.org/articles/10.3389/fgene.2025.1589259/full